NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH

Abstract Background: Based on the complex pathophysiology of type 2 diabetes and atherosclerosis we hypothesized a dynamic change in prognostic value of cardiovascular biomarkers over time. Methods: In this prospective study 746 patients with type 2 diabetes mellitus, being followed up for 60 months were analysed. The primary endpoint was defined as unplanned hospitalization for cardiovascular disease or death. Beside others, especially the prognostic performance of the biomarkers of interest (GDF-15, NT-proBNP, hs-TnT) was evaluated in relation to quartiles of diabetesduration.Results: In patients having a diabetes duration below 7 years lnGDF-15 (HR 2.84; p < 0.01) and lnhs-TnT (HR 2.96; p<0.01) were significant predictors of the primary endpoint. LnAge (HR 40.11; p < 0.01) and lnNT-proBNP (HR 1.61; p <0.01) were significant predictors in patients with a diabetes duration between 7 and 12 years. In the third quartile (diabetes duration 12-22 years) lnAge (HR 13.09; p =0.041), urinary albumin to creatinine ratio (HR 2.74; p = 0.001) and lnNT-proBNP (HR 1.81, p < 0.001) predicted the endpoint. In patients with a diabetes duration above 22 years, lnAge (HR 50.79; p = 0.002) and lnNT-proBNP (HR 2.1; p < 0.01) were the only significant predictors of the endpoint. Conclusion: Prognostic power of cardiovascular biomarkers changes dynamically in relation to duration of type 2 diabetes mellitus. In patients with shorter duration of the disease markers of subclinical cardiovascular dysfunction and inflammation perform better than markers of systemic advanced organ dysfunction and cardiovascular disease.

Download Full-text

Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2020.07.005 ◽

2020 ◽

Vol 132 ◽

pp. 36-43 ◽

Cited By ~ 1

Author(s):

Adam J. Nelson ◽

Ann Marie Navar ◽

Hillary Mulder ◽

Daniel Wojdyla ◽

Sephy Philip ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Type 2 Diabetes Mellitus ◽

Cardiovascular Risk ◽

Residual Cardiovascular Risk ◽

Bypass Angioplasty Revascularization Investigation

Download Full-text

A Study of QTc Prolongation as a Screening Tool for Cardiovascular Disease in Type 2 Diabetes Patients of Karad, India

Journal of Evolution of Medical and Dental Sciences ◽

10.14260/jemds/2021/598 ◽

2021 ◽

Vol 10 (34) ◽

pp. 2934-2938

Author(s):

Sanjay Tukaram Thorat ◽

Parikshit Gajanan Mankar ◽

Niyati Kaila ◽

Avanti Jaywant Damle ◽

Radhika Ratanlal Bajaj ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Type 2 Diabetes Mellitus ◽

Cardiovascular Risk ◽

Qt Interval ◽

Glycated Haemoglobin ◽

Qtc Interval ◽

Qtc Prolongation

BACKGROUND The occurrence of QT interval prolongation is higher in subjects with type 2 diabetes mellitus (T2DM). Duration of QT interval corrected (QTc) for heart rate is independently related with severity of cardiovascular diseases in diabetics. This study was proposed to assess the QTc prolongation as a diagnostic tool for cardiovascular disease in T2DM patients. METHODS This study included 100 diabetic patients admitted in wards of a tertiary care center. A thorough clinical examination was carried out for all the patients. Patients were investigated for the fasting blood glucose level, glycated haemoglobin (HbA1c), lipid profile & electrocardiogram (ECG). Data was represented as percentage. Mean and standard deviation (SD) of quantitative variables were tabulated, t test was used for correlation and receiver operating characteristic (ROC) curve was used for evaluating area under curve. P < 0.05 was considered statistically significant. RESULTS Male preponderance was observed. All the study subjects had a prolonged period of diabetes with various metabolic complications. The area under the curve estimation of QTc > 400 ms with respect to HbA1c and duration of diabetes showed significant correlation between longer duration of diabetes and raised HbA1c associated with raised QTc interval (P < 0.05). CONCLUSIONS Diagnosis of prolonged QTc interval could be utilized for estimating cardiovascular risk in diabetes patients. It can be easily assessed on ECG besides being a noninvasive investigation which is also affordable in evaluating the cardiovascular risk in T2DM patients. KEY WORDS Blood Glucose, Cardiovascular Diseases, Electrocardiography, Glycated Haemoglobin A, Long QT Syndrome, Type 2 Diabetes Mellitus

Download Full-text

Cardiovascular disease prevention and therapy in women with Type 2 diabetes

Future Cardiology ◽

10.2217/fca-2021-0011 ◽

2021 ◽

Author(s):

Camilla Cocchi ◽

Francesca Coppi ◽

Alberto Farinetti ◽

Anna Vittoria Mattioli

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Type 2 Diabetes Mellitus ◽

Cardiovascular Risk ◽

Risk Category ◽

Cvd Risk ◽

Men And Women ◽

Delay In Diagnosis

Cardiovascular disease (CVD) is the leading cause of death among men and women, although women are usually underdiagnosed and experience a delay in diagnosis. This also occurs in women with type 2 diabetes mellitus, despite the fact that diabetes is recognized as a major cardiovascular risk factor. Several factors influence the gap between diagnosis and treatment of cardiovascular disease in women: lack of perception of cardiovascular risk, effects of sex-related risk factors and the action of drugs in women. Women with Type 2 diabetes mellitus are more likely to be assigned a lower CVD risk category and to receive lifestyle counseling as well as less intensive CVD therapy compared with men. The present narrative review aims to analyze the risk of CVD in women with Type 2 diabetes mellitus and whether there is a difference between men and women in the efficacy of SGLT-2 inhibitors, new hypoglycemic drugs.

Download Full-text